



an Open Access Journal by MDPI

## Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches

Guest Editors:

**Prof. Dr. Jacek Tabarkiewicz**

Department of Human Immunology, College of Medical Science, Institute of Medicine, University of Rzeszów, Rzeszow, Poland

**Dr. Norbert Grząśko**

Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland; Department of Hematology, Center of Oncology of the Lublin Region St. Jana z Dukli, Lublin, Poland

Deadline for manuscript submissions:

**closed (31 July 2021)**

### Message from the Guest Editors

Dear Colleagues,

Despite advances in the understanding of hematological malignancies' pathophysiology, the treatment of hematological neoplasms remains challenging. Improving the therapeutic efficacy of existing therapies or developing a novel therapeutic agent is urgently needed. This Special Issue of Biomedicines, titled "Hematological Malignancy: From Pathophysiology to Novel Therapeutic Approaches" will include reviews that describe novel strategies for treating hematological malignancies developed over the past few years as well as original research articles that describe novel discoveries in the pathophysiology of hematological neoplasms and strategies for treating hematological malignancies using preclinical and/or translational studies. In addition, studies on biomarkers, combination therapy, drug responses, the tumor microenvironment, and mechanistic approaches will be accepted.

Prof. Dr. Jacek Tabarkiewicz  
*Guest Editor*



[mdpi.com/si/77703](https://mdpi.com/si/77703)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)